BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsEarnings

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for

Related news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

Stock data

Close
1.33 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States